机器人辅助部分肾切除术对比根治性肾切除术治疗cT2期肾细胞癌:一项全国配对分析
该多中心回顾性研究基于UroCCR网络前瞻性数据,将250例接受机器人辅助部分肾切除术(RAPN)与250例接受微创根治性肾切除术(RN)的cT2M0肾细胞癌患者按倾向性评分1:1匹配。结果显示两组5年无病生存率、癌症特异性生存率、无转移生存率和总生存率均无显著差异,但RAPN在肾功能保护方面更优,且主要并发症发生率更高(6% vs 2%,P=.04)。结论认为对经选择的cT2期患者,RAPN是安全且功能更优的替代方案。
要点
- RAPN与RN在cT2期肾癌的5年肿瘤学结局无显著差异
- RAPN肾功能保护更优,5年eGFR下降更少
- RAPN主要并发症发生率高于RN(6% vs 2%,P=.04)
核心结论
- 对经选择的cT2期肾细胞癌患者,RAPN是安全且功能优于RN的替代方案。
- RAPN围手术期并发症更高,但在专家中心风险可接受且被长期肾功能保护获益抵消。
研究设计与样本
- 多中心回顾性研究,使用UroCCR网络前瞻性收集数据(NCT03293563)。
- 纳入847例cT2M0肾细胞癌患者,按倾向性评分1:1匹配后RAPN组250例、RN组250例。
主要发现
- RAPN组与RN组中位肿瘤大小分别为8 cm和8.2 cm。
- RAPN与RN的5年无病生存率分别为61%和49%(P=.2),癌症特异性生存率分别为87%和94%(P=.8)。
- RAPN与RN的5年无转移生存率分别为71%和66%(P=.4),总生存率均为80%(P=.5)。
- RAPN组5年eGFR中位下降为-15 mL/min/1.73 m2,RN组为-23 mL/min/1.73 m2;RAPN组慢性肾病分期迁移更少、急性肾损伤更少。
- RAPN组主要并发症发生率为6%,RN组为2%(P=.04);RAPN组46%达到trifecta结局。
临床怎么用
- 对经选择的cT2期肾细胞癌患者,在专家中心可考虑RAPN以保护肾功能。
- RAPN需权衡更高的围手术期主要并发症风险(6% vs 2%)。
局限性
- 本研究为多中心回顾性研究,尽管使用倾向性评分匹配,仍可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radical nephrectomy (RN) remains the standard treatment for cT2 renal cell carcinoma (RCC), but partial nephrectomy has emerged as a viable alternative with the development of robot-assisted approaches. However, robust comparative data between robot-assisted partial nephrectomy (RAPN) and RN for large renal tumors remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study using prospectively collected data from the UroCCR network (NCT03293563). Patients undergoing RAPN or minimally invasive RN for cT2M0 RCC were matched 1:1 using propensity scores based on clinical and tumor characteristics. Primary outcome was 5-year disease-free survival. Secondary end points included overall survival, renal function, perioperative outcomes, complications, and trifecta achievement. RESULTS: Of 847 patients included, 250 RAPN and 250 RN were matched. The median tumor size was 8.2 cm in the RN group and 8 cm in the RAPN group. Oncologic outcomes were comparable: 5-year disease-free survival was 61% and 49% (P = .2), cancer-specific survival was 87% and 94% (P = .8), metastasis-free survival was 71% and 66% (P = .4), and overall survival was 80% and 80% (P = .5), for RAPN and RN, respectively. RAPN was associated with improved renal function preservation (median change in estimated glomerular filtration rate at 5 years: -15 vs -23 mL/min/1.73 m2), fewer chronic kidney disease stage migrations, and reduced acute kidney injury. Major complications were more frequent after RAPN (6% vs 2%, P = .04). The trifecta outcome was achieved in 46% of RAPN cases. CONCLUSIONS: RAPN is a safe and functionally superior alternative to RN for selected patients with cT2 RCC. While associated with higher perioperative morbidity, these risks are acceptable in expert centers and offset by long-term nephron-sparing benefits.
引用
- Et-Touzani R, Bernhard JC, Prudhomme T, et al. sPaRT2-Minimally Invasive Partial vs Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235). J Urol. 2026. PMID: 41962052. doi:10.1097/JU.0000000000005063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。